Merck Stock (MRK) in November 2025: Price, Latest News, Forecasts and Analyst Outlook
Merck & Co. is ending November 2025 on a strong note. A flurry of regulatory wins for cancer drug Keytruda, positive mid‑stage data for heart drug Winrevair, and fresh deal‑making have pushed the share price close to its 52‑week high and reignited debate about the stock’s upside as it heads toward the Keytruda patent cliff later this decade.
